Evidence map›Paper›PMID 40157906›Full record

ArticleCell death & disease2025

Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation.

Tania Rossi, Martina Valgiusti, Maurizio Puccetti, Giacomo Miserocchi, Michele Zanoni, Davide Angeli, Chiara Arienti, Ilaria Pace, Cristian Bassi, Ivan Vannini and 7 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tania RossiBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0002-8337-9372
Martina ValgiustiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Maurizio PuccettiAzienda Unità Sanitaria Locale di Imola, Imola, Italy.
Giacomo MiserocchiPreclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "DinoAmadori", Meldola, Italy.
Michele ZanoniBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0003-1826-9430
Davide AngeliUnit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Chiara ArientiImmuno-Gene Therapy Factory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0002-2265-828X
Ilaria PaceDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.ORCID http://orcid.org/0009-0003-7523-1161
Cristian BassiDepartment of Translational Medicine, Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA) Centre, University of Ferrara, Ferrara, Italy.ORCID http://orcid.org/0000-0002-5823-709X
Ivan VanniniPathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy.
Mattia MelloniDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.ORCID http://orcid.org/0000-0003-3987-7267
Erika BandiniBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Milena UrbiniBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.ORCID http://orcid.org/0000-0002-3364-9098
Massimo NegriniDepartment of Translational Medicine, Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA) Centre, University of Ferrara, Ferrara, Italy.ORCID http://orcid.org/0000-0002-0007-1920
Massimiliano Bonafè *Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Manuela Ferracin *Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.ORCID http://orcid.org/0000-0002-1595-6887
Giulia Gallerani *Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. g.gallerani@unibo.it.ORCID http://orcid.org/0000-0003-0121-9621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor dissemination is a key event in tumor progression. During this event, a main role is played by circulating tumor cells (CTCs), immune cells, and their interaction. How the immune system supports the survival and proliferation of CTCs is not fully elucidated. In this study we established an in-vitro co-culture system consisting of immune cells and CTCs from the same patient, which increased the success rate in the establishment of CTC-derived long-term cell cultures. In this system, we characterized the immune cells of successful co-cultures and the signals they exchange with cancer cells, including cytokines and extracellular vesicle (EV) content. Using this protocol, we stabilized four CTC-derived cell lines from patients with metastatic gastroesophageal cancer, which were cultured for over a year and characterized from a genetic and molecular point of view. The four cell lines harbor shared chromosomal aberrations including the amplification at 8q24.21 containing MYC and deletion 9p21.3 containing CDKN2A/B and the IFN type I cluster. The transcriptomic profile of CTC cell lines is distinct from primary tumors, and we detected the activation of E2F, G2M and MYC pathways and the downregulation of interferon response pathway. Each cell line shows a degree of invasiveness in zebrafish in-vivo, and the most invasive ones share the same mutation in RAB14 gene. In addition, the four cell lines secrete cell-line specific EVs containing microRNAs that target YAP, BRG1-AKT1, TCF8-HDAC pathways. Overall, we highlight how the immune system plays a key role in the proliferation of CTCs through EV signaling, and how CTC cell line genomic and transcriptomic alterations make these cells less visible from the immune system and likely responsible for the survival advantage in sites distant from the microenvironment of origin.

Indexed as

Esophageal NeoplasmsNeoplastic Cells, CirculatingStomach NeoplasmsAnimalsCell Line, TumorCell ProliferationCell SurvivalCoculture TechniquesGene Expression Regulation, NeoplasticHumansZebrafish

Identifiers

PMID40157906
PMCPMC11954855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.